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Abstract Further to the patent expiry of Neupogen®
(Amgen filgrastim), Hospira has developed a biosimilar
filgrastim (Nivestim™) that may offer a clinically effective
alternative for multiple hematologic and oncologic indica-
tions. Here results are reported from a phase I trial,
primarily designed to compare the pharmacodynamic
profiles of Hospira filgrastim and Amgen filgrastim. A
phase I, single-center, double-blind, randomized trial was
undertaken to demonstrate equivalence of the pharmacody-
namic characteristics of Hospira filgrastim and Amgen
filgrastim. Fifty healthy volunteers were randomized to
receive 5 or 10 µg/kg dosing, before further randomization
to treatment sequence. All volunteers received five daily
subcutaneous doses of Hospira filgrastim or Neupogen,
with subsequent crossover to the alternative treatment.
Bioequivalence was evaluated by analysis of variance; if
the estimated 90% confidence intervals (CIs) for the ratio of
‘test’ to ‘reference’ treatment means were within the
conventional equivalence limits of 0.80–1.25, then bio-
equivalence was concluded. Forty-eight volunteers com-
pleted the study. Geometric mean absolute neutrophil count
area under the curve from time 0 to the last time point at
day 5 (primary endpoint) was comparable in volunteers
given Hospira filgrastim or Amgen filgrastim at 5 µg/kg
(ratio of means, 0.98; 90% CI, 0.92–1.05) or 10 µg/kg
(ratio, 0.97; 90% CI, 0.93–1.01); 90% CIs were within the
predefined range necessary to demonstrate bioequivalence.
Hospira filgrastim was well tolerated with no additional
safety concerns over Amgen filgrastim. Hospira filgrastim
is bioequivalent with Amgen filgrastim with regard to its
pharmacodynamic characteristics.
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Introduction
Recombinant granulocyte colony-stimulating factor (G-
CSF; filgrastim) has formed an integral part of supportive
therapy across multiple oncologic and hematologic indica-
tions under the trade name Neupogen® (Amgen filgrastim;
Amgen Inc., Thousand Oaks, CA, USA) [1–3]. Hospira has
developed a biosimilar version of filgrastim (Hospira
filgrastim, Nivestim™), which could potentially provide a
clinically effective alternative to Amgen filgrastim.
The current use of Amgen filgrastim and the early
development of Hospira filgrastim have been described
previously in this journal as part of a study that
demonstrated the bioequivalence of the two filgrastims in
terms of their pharmacokinetic (PK) characteristics [4].
This published study was the first of two randomized, phase
I trials conducted to compare the properties of Hospira
filgrastim and Amgen filgrastim in healthy volunteers.
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trial, which was primarily designed to compare the
pharmacodynamic (PD) profiles of Hospira filgrastim and
Amgen filgrastim following administration of multiple,
consecutive subcutaneous (s.c.) doses at two dose levels
(5 or 10 µg/kg). PK and safety assessments were secondary
objectives of the study.
Design and methods
Eligibility
The study protocols and all amendments were approved by
a local research ethics committee and the UK Medicines
and Healthcare Products Regulatory Agency. All volunteers
gave written informed consent before any study-specific
procedures were undertaken. Volunteers were free to
withdraw from the study at any time.
Healthy, non-smoking, male or female volunteers aged
18–50 years, with a body mass index of 19–30 kg/m
2
and a body weight of 50–110 kg, were recruited.
Exclusion criteria were identical to those described for
the previously reported phase I PK study of Hospira
filgrastim, except for those specifically relating to i.v. drug
administration [4]. Concurrent use of prescription or over-
the-counter medicines (excluding hormonal contraceptives
and occasional use of paracetamol) was not permitted.
Similarly, caffeine- and alcohol-containing beverages were
not allowed during the assessment periods or in the 24 h
prior to first dose.
Study design and outcomes
Volunteers were treated at Charles River Clinical Services,
Edinburgh, UK, between November 2, 2006 and January
24, 2007, as part of a randomized, double-blind,
comparator-controlled, two-way, crossover trial. Volunteers
were randomized to one of two dose levels (5 or 10 µg/kg)
before further randomization to order of agent administra-
tion. An initial screening period of up to 21 days was
followed by two 10-day assessment periods, separated by a
washout period of at least 13 days. Volunteers received a
total of five s.c. injections of Hospira filgrastim (at one of
the two doses) or Amgen filgrastim (at a matching dose
level) over five consecutive days, at approximately the
same time each day, with crossover to the alternative study
drug in the second assessment period. Randomization was
performed according to a computer-generated randomiza-
tion list, produced by Constella Group Ltd, Abingdon, UK.
Conditions relating to provision of meals, fasting periods,
overnight stays, and levels of permitted physical activity
were standardized throughout.
The primary endpoint was absolute neutrophil count
(ANC) area under the curve from time 0 to the last time
point (AUC0–tlast ) at day 5, while secondary endpoints
included ANC time at which maximum observed plasma
concentration (Cmax) occurred (Tmax), ANCmax, ANCmin,
and CD34+ cell count, also at day 5. Secondary PK
endpoints included Cmax, minimum concentration observed
(Cmin), Tmax, elimination half life (T1/2), AUC0–tlast, AUC
from time 0 to 24 h (AUC0–24 h), AUC from 0 to infinity
(AUC0–infinity), terminal elimination rate constant (λz), and
clearance for plasma concentration of G-CSF at day 5.
Safety was also assessed.
Blood samples were collected for measurement of
plasma G-CSF at −1 h on days 1–4 and at −1, 0.25, 0.5,
0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 h post dose on day 5
of each assessment period. For PD (ANC) analysis, samples
were collected at −1 h on days 1–4 and at −1, 0.5, 1, 2, 4, 6,
8, 24, 48, 72, 96, and 120 h following dose administration
on day 5. For determination of CD34+ cell counts, samples
were collected on days 1 (predose), 3 (6 h post dose), 5 (6 h
post dose), 7 (48 h post dose), and 10 (120 h post dose). G-
CSF concentrations were assessed by the Charles River
Laboratories Central Laboratory using a validated commer-
cial assay [5–9]. CD34+ cell counts were determined in the
same laboratory using a commercial flow cytometry kit
(Stem-Kit
TM, Beckman Coulter, High Wycombe, UK) that
was validated in house. Cells were labeled using a
phycoerythrin-conjugated anti-CD34 monoclonal antibody,
and analyzed using a COULTER® EPICS® XL
TM Flow
Cytometer.
Safety was assessed based on observed adverse events
(AEs), clinical laboratory tests (hematology, biochemistry,
and urinalysis), physical examination, results of 12-lead and
30-min continuous ECG, vital sign assessments, chest X-
rays, and G-CSF antibody analysis.
Statistical analysis
The PD, PK, and safety populations were defined as
described previously [4]. In the PK analysis, λz and
derivative parameters were not estimated for volunteers
whose plasma concentration–time profiles in the terminal
(log-linear) phase were not clearly defined with at least
three quantifiable concentrations.
ANC Tmax and Tmax, λz, and clearance for plasma
concentration of G-CSF were summarized descriptively
only. All other PK and PD parameters were loge trans-
formed prior to statistical analysis and presented as
geometric means, along with other summary statistics.
Missing concentrations were deleted, resulting in an
interpolation between the nearest two values. Outliers were
identified using an outlier check (T procedure). PK data
were analyzed by non-compartmental methods using
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Bioequivalence was assessed for the primary and
secondary endpoints using a mixed effects analysis of
variance as described previously. If the 90% confidence
interval (CI) for the ratio of ‘test’ to ‘reference’ means was
completely within the conventional bioequivalence limits of
0.80–1.25, then bioequivalence was concluded.
A total of 48 evaluable volunteers were required for 80%
power (α=0.05) to demonstrate bioequivalence between
Hospira filgrastim and Amgen filgrastim, assuming a
within-volunteer coefficient of variation of 23% and an
equivalence range of ±20% in the ‘test’ to ’reference’ mean
ratio for ANC AUC0–tlast at day 5.
Results
Volunteer disposition
A total of 50 volunteers were enrolled: 24 into the 5-µg/kg
dose group and 26 into the 10-µg/kg dose group (Fig. 1).
Two volunteers in the 10-µg/kg dose group did not
complete the study: one withdrew due to an AE (moderate
musculoskeletal chest pain and mild back pain after
completing the 5-day course of Amgen filgrastim and
3 days of Hospira filgrastim) and one withdrew for personal
reasons (after completing the 5-day course of Amgen
filgrastim). These volunteers were excluded from the PD
and PK analyses. One further volunteer in the 10-µg/kg
dose group was excluded from the PD analyses because of
insufficient data (missing last time point). One additional
volunteer in the 5-µg/kg dose group was excluded from the
PK analyses for the same reason. All volunteers were
evaluable for safety.
Investigators permitted several volunteers to take para-
cetamol for pain relief; however, this was not considered to
affect study outcomes and therefore volunteers were not
withdrawn. Baseline demographics were generally well
matched between groups, although the proportion of
Caucasian volunteers was slightly higher in the 5-µg/kg
dose group than in the 10-µg/kg dose group, and
accordingly the proportion of Black volunteers was slightly
higher in the 10-µg/kg dose group than in the 5 µg/kg
group (Table 1).
Pharmacodynamics
The primary PD endpoint (geometric mean ANC AUC0–tlast
at day 5) was similar in volunteers who received Hospira
filgrastim or Amgen filgrastim in both the 5-µg/kg (ratio of
means, 0.98; 90% CI, 0.92–1.05) and 10-µg/kg (ratio of
means, 0.97; 90% CI, 0.93–1.01) dose groups (Table 2).
For both dose groups, 90% CIs were within the predefined
range necessary to demonstrate bioequivalence of the two
agents. The ANC profiles at both dose levels confirmed the
similarity of Hospira filgrastim and Amgen filgrastim
(Fig. 2). Secondary PD parameters were also generally
similar between volunteers given Hospira filgrastim or
Amgen filgrastim in both dose groups (Table 2). The only
difference was that ANC Tmax at day 5 in the 10-µg/kg dose
group occurred slightly earlier with Hospira filgrastim than
with Amgen filgrastim (geometric mean, 7.85 vs. 9.45 h,
respectively). In the 5-µg/kg dose group, ANC Tmax at day
5 was similar following administration of either Hospira
filgrastim or Amgen filgrastim (geometric mean, 7.81 vs.
7.80 h, respectively). Ninety percent CIs for ANC Cmax,
ANC Cmin, and CD34+ cell counts at day 5 were all within
the predefined range required to demonstrate bioequiva-
lence of the two agents.
Further analysis of CD34+ cell counts supported the
bioequivalence of Hospira filgrastim and Amgen filgrastim.
Geometric mean CD34+ cell counts remained similar with
both agents, regardless of dose or time point (Fig. 3). The
maximum mean CD34+ cell count (day 5) was 47.2 cells/μl
(95% CI, 36.1–61.7) with Hospira filgrastim and 46.0 cells/
μl (95% CI, 33.6–63.0) with Amgen filgrastim in the 5-µg/
kg dose group. The maximum mean CD34+ cell counts
were also similar with each agent in the 10-µg/kg dose
group: 81.9 cells/μl (95% CI, 64.5–104.0) with Hospira
filgrastim and 77.5 cells/μl (95% CI, 59.4–101.3) with
Amgen filgrastim.
Pharmacokinetics
Following multiple dosing with 5 µg/kg s.c. Hospira
filgrastim and Amgen filgrastim, the ratios of geometric
means for AUC0–tlast, AUC0–24 h, Cmax and Cmin at day 5
were 1.11 (90% CI, 1.00–1.23), 1.11 (90% CI, 1.00–1.23),
1.13 (90% CI, 0.99–1.27), and 1.01 (90% CI, 0.90–1.15),
respectively. The 90% CIs for AUC0–tlast, AUC0–24 h, and
Cmin were within the range required to show bioequivalence
of the two drugs. The upper CI for Cmax was slightly above
the predefined upper equivalence limit of 1.25, but if
outliers were excluded (n=2), 90% CIs for Cmax were
shown to be within the predefined equivalence limits (ratio
of means, 1.08; 90% CI, 0.97–1.21). Mean Tmax at day 5
occurred slightly earlier after administration of Amgen
filgrastim 5 μg/kg compared with Hospira filgrastim 5 μg/
kg (3.83 vs. 4.21 h, respectively).
Following multiple dosing with 10 µg/kg s.c. Hospira
filgrastim and Amgen filgrastim, geometric mean ratios
of 1.10 (90% CI, 0.97–1.26), 1.10 (90% CI, 0.97–1.26),
1.17 (90% CI, 1.03–1.32), and 1.05 (90% CI, 0.92–1.20)
were reported for AUC0–tlast, AUC0–24 h, Cmax,a n dCmin
at day 5, respectively. Hospira filgrastim and Amgen
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not for AUC0–tlast, AUC0–24 h,a n dCmax, as the upper CIs
for these parameters were slightly above the predefined
upper equivalence limit. If outliers were excluded (n=3),
however, 90% CIs for AUC0–tlast and AUC0–24 h were
shown to be within the predefined equivalence limits (for
both parameters, ratio of means, 1.07; 90% CI, 0.97–1.17).
Mean Tmax at day 5 occurred slightly later after adminis-
tration of Amgen filgrastim 10 µg/kg compared with
Hospira filgrastim 10 µg/kg (4.37 vs. 3.55 h, respectively).
AUC0–infinity and T1/2 were not analyzed due to missing
data.
Safety
The incidence of AEs in volunteers given Hospira filgrastim
was slightly lower than that observed in volunteers given
Amgen filgrastim in both the 5-µg/kg (79% vs. 83%,
respectively) and 10-µg/kg (77% vs. 92%, respectively)
dose groups (Table 3). The incidence of AEs related to the
Fig. 1 Study design and volunteer disposition. Superscript a All
volunteers who received ≥1 dose of study medication; superscript b
all volunteers who completed the study with a sufficient number of
quantifiable concentrations to warrant parameter estimation in both
assessment periods; superscript c all volunteers for whom an
evaluable PD parameter was obtained in both assessment periods;
superscript d volunteer withdrew
Variable 5µg/kg dose (n=24) 10µg/kg dose (n=26)
Male gender, n (%) 15 (62.5) 16 (61.5)
Mean age, years (SD) 31.6 (8.6) 29.2 (6.9)
Ethnicity, n (%)
Caucasian 23 (95.8) 20 (76.9)
Black 1 (4.2) 5 (19.2)
Asian 0 (0) 0 (0)
Other 0 (0) 1 (3.8)
Mean height, cm (SD) 172.5 (8.2) 171.0 (9.4)
Mean weight, kg (SD) 75.8 (11.4) 73.0 (12.8)
Mean BMI, kg/m
2 (SD) 25.4 (3.0) 24.8 (3.1)
Table 1 Baseline demographics
SD standard deviation, BMI
body mass index
974 Ann Hematol (2010) 89:971–978study drug was also slightly lower in volunteers who
received Hospira filgrastim compared with those who
received Amgen filgrastim in the 10-µg/kg dose group
(77% vs. 88%, respectively), but was similar in both
subsets of volunteers in 5-µg/kg dose group (75% with
both agents).
The most common AEs were back pain and headache
(Table 3), most of which were related to the study drug.
Only minor differences in AE profiles were observed
between Hospira filgrastim and Amgen filgrastim (Table 3).
No serious AEs were reported and all AEs were mild or
moderate in intensity, with the exception of two events:
Fig. 2 Mean ANC over time in
subjects given Hospira filgras-
tim or Amgen filgrastim;
a 5-µg/kg dose group and
b 10-µg/kg dose group. Data
shown are geometric means.
Samples taken outside each
schedule timepoint window
have been excluded. ANC
absolute neutrophil count,
AUC0–tlast area under the curve
from time 0 to the last time
point, CI confidence interval
Geometric mean (range)
PD parameter Hospira filgrastim Amgen filgrastim Ratio 90% CI
5 µg/kg dose (n=24)
ANC AUC0–tlast, pg h/ml 1,633 (918–2,633) 1,660 (696–2,535) 0.98 0.92–1.05
a
ANC Cmax, ×10
9 h/l 36.09 (24.12–52.19) 35.66 (18.14–58.17) 1.01 0.96–1.07
a
ANC Cmin, ×10
9 h/l 3.39 (1.01–8.32) 3.82 (1.71–7.83) 0.89 0.80–0.98
a
ANC Tmax, h 7.81 (6.00–8.00) 7.80 (6.00–24.00) ––
CD34+ count, cells/µl 47.2 (14.0–158.0) 46.0 (12.0–187.0) 1.03 0.85–1.24
a
10 µg/kg dose (n=23)
ANC AUC0–tlast, pg h/ml 2,170 (1,091–3,341) 2,249 (1,099–3,970) 0.97 0.93–1.01
a
ANC Cmax, ×10
9 h/l 46.10 (30.53–69.65) 47.20 (25.09–66.44) 0.98 0.95–1.01
a
ANC Cmin, ×10
9 h/l 3.01 (1.86–6.11) 3.24 (1.69–4.90) 0.93 0.83–1.04
a
ANC Tmax, h 7.85 (4.00–24.00) 9.45 (6.00–24.07) ––
CD34+ count, cells/µl 82 (19–184) 78 (28–232) 1.06 0.90–1.24
a
Table 2 Summary of PD data
– not reported
a The 90% CI was within the
predefined equivalence range of
0.80–1.25, demonstrating bioequi-
valence between the two agents
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grastim 10 µg/kg; and severe muscle spasms following
administration of Hospira filgrastim 5 µg/kg. Both of these
AEs were considered to be related to study medication.
Laboratory data demonstrated: increases in lymphocyte,
monocyte, eosinophil, basophil, and large unclassified cell
counts; reductions in platelet counts; elevations in alkaline
phosphatase, phosphate, lactate dehydrogenase and uric
acid; and decreases in bilirubin. None of these changes
were different between the study drugs. Two volunteers had
clinically significant hematologic abnormalities (decreased/
increased platelet count) and a further six had biochemistry
abnormalities (increased gamma glutamyl transferase
[GGT; n=3]; alanine aminotransferase [ALT; n=1]; GGT
and ALT [n=1]; and GGT, ALT, and lactate dehydgroge-
nase [n=1]). These changes occurred with both study
drugs. No clinically significant changes in blood pressure,
urinalysis, and physical examination were reported.
Discussion
According to guidelines issued by the European Medicines
Agency (EMA), biosimilar medicinal products containing
filgrastim should demonstrate comparability with Amgen
filgrastim [10]. The EMA recommends a series of preclin-
ical and clinical studies, including PD investigations in
healthy volunteers, preferably at multiple-dose levels, with
ANC as the primary endpoint and CD34+ cell count as a
secondary parameter. The phase I PD study reported here
was designed to fulfill EMA guidelines and forms part of
the regulatory assessment for Hospira filgrastim.
Bioequivalence of the two filgrastims was demonstrated
for all PD parameters tested (including ANC AUC0–tlast
[primary endpoint]) at 5 or 10 µg/kg doses. The only
difference between the two agents was that ANC Tmax at
day 5 in the 10-µg/kg dose group occurred slightly earlier
with Hospira filgrastim than with Amgen filgrastim, but
this is unlikely to have any clinical significance. Data on
CD34+ cells demonstrate that Hospira filgrastim is equiv-
alent to Amgen filgrastim for the mobilization of peripheral
blood progenitor cells (PBPCs). This shows that Hospira
filgrastim has potential for use as a growth factor to support
autologous and allogeneic PBPC transplantation, indica-
tions where G-CSF has been used successfully for many
years [11].
PK analyses largely supported the bioequivalence of
Hospira filgrastim and Amgen filgrastim. However, for
Fig. 3 Mean CD34+ cell count
over time in subjects given
Hospira filgrastim or Amgen
filgrastim; a 5-µg/kg dose
group and b 10-µg/kg dose
group. Data shown are
geometric mean values with
lower and upper 95%
confidence intervals
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concluded when outliers (as are commonly observed in
studies of this kind [12, 13]) were excluded. Bioequiva-
lence could not be shown for Cmax at day 5, even when
outliers were excluded. There was also some slight
variability between the two agents in terms of Tmax at day
5 at both dose levels.
While some PK parameters did not meet the prespecified
bioequivalence limits for the 90% CI for the ratio of ‘test’
to ‘reference’ means, it should be considered that this study
was primarily designed to evaluate PD characteristics and
was not specifically designed to detect differences in PK.
Furthermore, studies have indicated that there are PD–PK
interactions between neutrophils and G-CSF, since neutro-
phils appear to contribute to G-CSF clearance [14]. This
effect could have confounded the PK data, and it is
therefore unsurprising that the bioequivalence of Hospira
filgrastim and Amgen filgrastim was not demonstrated by
all PK parameters.
Hospira filgrastim was generally well tolerated, with
no unexpected toxicities. The AE profiles of Hospira
filgrastim and Amgen filgrastim were comparable in
terms of their nature and intensity, and similar to those
reported previously for recombinant G-CSF in healthy
volunteers [15]. The biochemical abnormalities were not
considered to be related to study medication, but may
instead have been caused by environmental stimuli or
metabolic changes. However, mild reversible elevations in
lactate dehydrogenase, alkaline phosphatase, and uric acid,
and decreases in bilirubin, have been reported previously
with G-CSF [8, 16]. The general hematopoietic effect of
G-CSF on lymphocytes, monocytes, basophils, and eosi-
nophils is also well documented in the literature [15, 17–
19].
In conclusion, this study builds on evidence from the
phase I PK study (previously reported in this journal) to
support the further clinical evaluation of Hospira filgrastim.
In line with this, results were recently reported from a large,
randomized, double-blind, phase III trial of Hospira
filgrastim versus Amgen filgrastim in patients receiving
myelosuppressive chemotherapy for the treatment of breast
cancer [20]. Data from these studies indicate that Hospira
filgrastim is well tolerated and may provide a clinically
effective alternative to Amgen filgrastim for a range of
indications in which G-CSF is routinely used.
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